Abstracts Archive - Page 2409 of 2607 - ACR Meeting Abstracts

Abstract Number: 327 • 2013 ACR/ARHP Annual Meeting
Major Differences In The Pattern Of Joint Swelling and Tenderness In a Large Psoriatic Arthritis Cohort – Results From An Exploratory Hierarchical Cluster Analysis
Burkhard Möller¹, Daniel Stekhoven² and Peter M. Villiger³, ¹Rheumatology, Inselspital, Bern, Switzerland, ²Swiss Clinical Quality Management in Rheumatic Diseases-SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) shows the largest complexity in joint involvement among all inflammatory types of arthritis. In order to improve feasibility and to reduce…
Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Philip J. Mease¹, Emily Edson-Heredia², Katherine C. Saunders³, Catherine L. Shuler², Baojin Zhu², Monica Chaudhari⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Eli Lilly and Company, Indianapolis, IN, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…
Abstract Number: 329 • 2013 ACR/ARHP Annual Meeting
Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry
Lars Törnqvist¹, Tomas Husmark², Ulla R. C. Lindqvist³, Gerd-Marie Alenius⁴, Per Larsson⁵, Annika Teleman⁶, Mats Geijer⁷, Lars Erik Kristensen⁸, Ingrid Thyberg⁹ and Elke Theander¹⁰, ¹Department of Rheumatology, Skåne University Hospital Malmö, Lund University, Sweden, Malmö, Sweden, ²Department of Rheumatology, Falu Hospital, Falun, Sweden, ³Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, ⁴Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁵Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁷Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Rheumatology, Linköping University Hospital, Linkoping, Sweden, ¹⁰Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Studies on early psoriatic arthritis (ePsA) are still rare and data on health related quality of life (HRQoL) in ePsA are lacking completely. To…
Abstract Number: 330 • 2013 ACR/ARHP Annual Meeting
Proteomic Profiling Of Synovial Fluid For The Identification Of Psoriatic Arthritis Soluble Biomarkers
Daniela Cretu^1,2, Fawnda Pellett³, Rajiv Gandhi⁴, Eleftherios Diamandis^5,6,7 and Vinod Chandran³, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada, ²Department of Pathology and Lab Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University Health Network, Arthritis Program, Toronto, ON, Canada, ⁵Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁶Department of Pathology and Lab Medicine, Mount Sinai Hospital, Department of Pathology and Lab Medicine, Toronto, ON, Canada, ⁷Deaprtment of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in patients seen in dermatology clinics. Identifying soluble biomarkers for PsA will help in…
Abstract Number: 331 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Georg Schett¹, Philip J. Mease², Dafna D. Gladman³, Arthur Kavanaugh⁴, Adewale O. Adebajo⁵, Juan J. Gomez-Reino⁶, Jürgen Wollenhaupt⁷, Maurizio Cutolo⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California San Diego, San Diego, CA, ⁵Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁶Hospital Clinico Universitario, Santiago, Spain, ⁷Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁸University of Genova, Genova, Italy, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
Abstract Number: 332 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
Zohair Abbas¹ and Marina N. Magrey², ¹Rheumatology, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, ²Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part…
Abstract Number: 333 • 2013 ACR/ARHP Annual Meeting
Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman¹ and Vinod Chandran¹, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with progressive joint damage and disability. In the last 15 years, tumour necrosis factor inhibitors…
Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Michael Lucke¹, Soo Hyun Kim² and M. Elaine Husni³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…
Abstract Number: 335 • 2013 ACR/ARHP Annual Meeting
Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
Sabrina Hoa¹, Denis Choquette², Louis Bessette³, Diane Sauvageau⁴, Boulos Haraoui⁴, Jean Pierre Pelletier², Jean-Pierre Raynauld⁴, Edith Villeneuve⁴ and Louis Coupal², ¹Rheumatology, Centre hospitalier de l'université de Montréal (Hôpital Notre-Dame), Montréal, QC, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: No long term head-to-head comparative studies of anti-TNF agents in psoriatic arthritis have been published. Controversy exists over the selection of initial biologic therapy…
Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…
Abstract Number: 337 • 2013 ACR/ARHP Annual Meeting
Fatigue and Work Disability In Psoriatic Arthritis
Jessica Walsh¹, Molly McFadden², Gerald G. Krueger³, Allen D. Sawitzke¹ and Daniel O. Clegg⁴, ¹Rheumatology, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah, SLC, UT, ³Dermatology, University of Utah, Salt Lake City, UT, ⁴Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT
Background/Purpose: Fatigue and work disability (WD) are common in people with psoriatic arthritis (PsA). Pain and discomfort from PsA contribute to fatigue by impairing sleep…
Abstract Number: 338 • 2013 ACR/ARHP Annual Meeting
Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage
Yasser El Miedany¹, Maha El Gaafary², Sally Youssef³ and Annie Nasr⁴, ¹Rheumatology, Medway Hospital, Gillingham, United Kingdom, ²Community, Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt, ³Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁴Radiology, Ain Shams University, Cairo, Egypt
Background/Purpose: To evaluate the use of musculoskeletal US as a predictor for inflammatory structural progression in psoriatic patients Methods: Measures of association (OR) were tested,…
Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…
Abstract Number: 300 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides
Monalyn Labitigan¹, Asha Shrestha¹, George W. Reed^2,3, Robert P. Magner⁴, Nicole Jordan⁵, Joel M. Kremer⁶, Jeffrey D. Greenberg⁷, Asena Bahce-Altuntas⁵ and Anna R. Broder¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²CORRONA, Inc., Southborough, MA, ³Orthopedics, University of Massachusetts Medical School, Worcester, MA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: Psoriatic Arthritis (PsA) is linked to both obesity and an increased cardiovascular risk. However, the relationship between PsA disease activity and lipids, a major cardiovascular…
Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Odirlei Andre Monticielo¹, Karen Regina Rosso Schons², Cristiane Faccin Knob², Walter Neumaier², Maristela de Oliveira Beck² and André Avelino Costa Beber², ¹Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal de Santa Maria, Santa Maria, Brazil
Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].